Work

Wild-type Presenilin 1 Protects against Alzheimer Disease Mutation-induced Amyloid Pathology

Year: 2006
Type: article
Abstract: Mutations in presenilin 1 (PS1) lead to dominant inheritance of early onset familial Alzheimer disease (FAD). These mutations are known to alter the γ-secretase cleavage of the amyloid precursor protein, resulting in increased ratio of Aβ42/Aβ40 and accelerated amyloid plaque pathology in transgenic mouse models. To investigate the factors that drive the Aβ42/Aβ40 ratio and amyloid pathogenesis and to investigate the possible interactions between wild-type and FAD mutant PS1, which are co-expressed in transgenic animals, we expressed the PS1 M146V knock-in allele either on wild-type PS1 (PS1M146V/+) or PS1 null (PS1M146V/–) background and crossed these alleles with the Tg2576 APP transgenic mice. Introduction of the PS1 M146V mutation on Tg2576 background resulted in earlier onset of plaque pathology. Surprisingly, removing the wild-type PS1 in the presence of the PS1 M146V mutation (PS1M146V/–) greatly exacerbated the amyloid burden; and this was attributed to a reduction of γ-secretase activity rather than an increase in Aβ42. Our findings establish a protective role of the wild-type PS1 against the FAD mutation-induced amyloid pathology through a partial loss-of-function mechanism. Mutations in presenilin 1 (PS1) lead to dominant inheritance of early onset familial Alzheimer disease (FAD). These mutations are known to alter the γ-secretase cleavage of the amyloid precursor protein, resulting in increased ratio of Aβ42/Aβ40 and accelerated amyloid plaque pathology in transgenic mouse models. To investigate the factors that drive the Aβ42/Aβ40 ratio and amyloid pathogenesis and to investigate the possible interactions between wild-type and FAD mutant PS1, which are co-expressed in transgenic animals, we expressed the PS1 M146V knock-in allele either on wild-type PS1 (PS1M146V/+) or PS1 null (PS1M146V/–) background and crossed these alleles with the Tg2576 APP transgenic mice. Introduction of the PS1 M146V mutation on Tg2576 background resulted in earlier onset of plaque pathology. Surprisingly, removing the wild-type PS1 in the presence of the PS1 M146V mutation (PS1M146V/–) greatly exacerbated the amyloid burden; and this was attributed to a reduction of γ-secretase activity rather than an increase in Aβ42. Our findings establish a protective role of the wild-type PS1 against the FAD mutation-induced amyloid pathology through a partial loss-of-function mechanism. The pathological hallmark defining Alzheimer disease (AD) 3The abbreviations used are: AD, Alzheimer disease; FAD, familial Alzheimer disease; Aβ, β-amyloid peptide; APP, amyloid precursor protein; CTF, carboxyl-terminal fragments; PS1, presenilin 1; TBS, Tris-buffered saline; ELISA, enzyme-linked immunosorbent assay; CHAPSO, 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonic acid; FL, full-length; PBS, phosphate-buffered saline; Bicine, N,N-bis(2-hydroxyethyl)glycine; BACE1, β-bite APP-cleaving enzyme.3The abbreviations used are: AD, Alzheimer disease; FAD, familial Alzheimer disease; Aβ, β-amyloid peptide; APP, amyloid precursor protein; CTF, carboxyl-terminal fragments; PS1, presenilin 1; TBS, Tris-buffered saline; ELISA, enzyme-linked immunosorbent assay; CHAPSO, 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonic acid; FL, full-length; PBS, phosphate-buffered saline; Bicine, N,N-bis(2-hydroxyethyl)glycine; BACE1, β-bite APP-cleaving enzyme. is the deposition of β-amyloid plaques of which the principal components are 40–42-amino acid peptides referred to as the β-amyloid peptides (Aβ), which are derived by proteolytic cleavages of the amyloid precursor protein (APP). APP is processed by at least three proteinases known as α-, β-, and γ-secretases. Both α- and β-secretases (BACE1) process APP in the extracellular domain with α-secretase cleavage occurring inside the Aβ domain and BACE1 at the amino terminus of Aβ. These proteolytic events generate APP carboxyl-terminal fragments (CTF), which serve as substrates for subsequent γ-secretase processing, producing either p3 (product of α- and γ-secretases) or Aβ peptides (product of BACE1 and γ-secretase) (reviewed in Ref. 1Wilquet V. De Strooper B. Curr. Opin. Neurobiol. 2004; 14: 582-588Crossref PubMed Scopus (200) Google Scholar). The γ-secretase activity is executed by a high molecular weight complex of which presenilin 1 (PS1) is an essential component (reviewed in Ref. 2Iwatsubo T. Curr. Opin. Neurobiol. 2004; 14: 379-383Crossref PubMed Scopus (150) Google Scholar). As such, inhibition of PS1 leads to the accumulation of APP-CTF (3De Strooper B. Saftig P. Craessaerts K. Vanderstichele H. Guhde G. Annaert W. Von Figura K. Van Leuven F. Nature. 1998; 391: 387-390Crossref PubMed Scopus (1532) Google Scholar, 4Yu H. Saura C.A. Choi S.Y. Sun L.D. Yang X. Handler M. Kawarabayashi T. Younkin L. Fedeles B. Wilson M.A. Younkin S. Kandel E.R. Kirkwood A. Shen J. Neuron. 2001; 31: 713-726Abstract Full Text Full Text PDF PubMed Scopus (217) Google Scholar, 5Feng R. Rampon C. Tang Y.P. Shrom D. Jin J. Kyin M. Sopher B. Miller M.W. Ware C.B. Martin G.M. Kim S.H. Langdon R.B. Sisodia S.S. Tsien J.Z. Neuron. 2001; 32: 911-926Abstract Full Text Full Text PDF PubMed Scopus (404) Google Scholar). The γ-secretase exhibits relaxed sequence specificity (6Lichtenthaler S.F. Wang R. Grimm H. Uljon S.N. Masters C.L. Beyreuther K. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 3053-3058Crossref PubMed Scopus (192) Google Scholar). In addition to APP and in an extracellular cleavage-dependent manner, PS1 has been implicated in the processing of a growing list of type I membrane proteins including Notch (7De Strooper B. Annaert W. Cupers P. Saftig P. Craessaerts K. Mumm J.S. Schroeter E.H. Schrijvers V. Wolfe M.S. Ray W.J. Goate A. Kopan R. Nature. 1999; 398: 518-522Crossref PubMed Scopus (1775) Google Scholar), N- and E-cadherins (8Marambaud P. Wen P.H. Dutt A. Shioi J. Takashima A. Siman R. Robakis N.K. Cell. 2003; 114: 635-645Abstract Full Text Full Text PDF PubMed Scopus (420) Google Scholar, 9Marambaud P. Shioi J. Serban G. Georgakopoulos A. Sarner S. Nagy V. Baki L. Wen P. Efthimiopoulos S. Shao Z. Wisniewski T. Robakis N.K. EMBO J. 2002; 21: 1948-1956Crossref PubMed Scopus (613) Google Scholar), and the tyrosinase family of proteins (Ref. 10Wang R. Tang P. Wang P. Boissy R.E. Zheng H. Proc. Natl. Acad. Sci. U. S. A. 2006; 103: 353-358Crossref PubMed Scopus (80) Google Scholar and reviewed in Ref. 11Kopan R. Ilagan M.X. Nat. Rev. Mol. Cell Biol. 2004; 5: 499-504Crossref PubMed Scopus (488) Google Scholar). Besides the γ-sites that generate Aβ40 and Aβ42, PS1-dependent proteolysis also occurs at other positions including the ξ-site (Aβ46) and ε-site (Aβ49) (12Sastre M. Steiner H. Fuchs K. Capell A. Multhaup G. Condron M.M. Teplow D.B. Haass C. EMBO Rep. 2001; 2: 835-841Crossref PubMed Scopus (422) Google Scholar, 13Weidemann A. Eggert S. Reinhard F.B. Vogel M. Paliga K. Baier G. Masters C.L. Beyreuther K. Evin G. Biochemistry. 2002; 41: 2825-2835Crossref PubMed Scopus (315) Google Scholar, 14Zhao G. Cui M.Z. Mao G. Dong Y. Tan J. Sun L. Xu X. J. Biol. Chem. 2005; 280: 37689-37697Abstract Full Text Full Text PDF PubMed Scopus (122) Google Scholar). Recent evidence supports a sequential cleavage model in which ε-cleavage at the cytosol-membrane junction serves as the initial cutting site followed by ξ- and γ-processing within the membrane (14Zhao G. Cui M.Z. Mao G. Dong Y. Tan J. Sun L. Xu X. J. Biol. Chem. 2005; 280: 37689-37697Abstract Full Text Full Text PDF PubMed Scopus (122) Google Scholar). Therefore, although Aβ40 and Aβ42 are measurements of specific products of γ-secretase cleavage of APP, levels of the CTF of APP as well as other PS1 substrates, which result from insufficient PS1-dependent processing, inversely correlate with total γ-secretase activity. Mutations in PS1 lead to autosomal dominant inheritance of familial Alzheimer disease (FAD). These mutations are known to enhance the ratio of Aβ42/Aβ40 and to foster the β-amyloid plaque pathology in transgenic mouse models (15Duff K. Eckman C. Zehr C. Yu X. Prada C.M. Perez-tur J. Hutton M. Buee L. Harigaya Y. Yager D. Morgan D. Gordon M.N. Holcomb L. Refolo L. Zenk B. Hardy J. Younkin S. Nature. 1996; 383: 710-713Crossref PubMed Scopus (1307) Google Scholar, 16Borchelt D.R. Thinakaran G. Eckman C.B. Lee M.K. Davenport F. Ratovitsky T. Prada C.M. Kim G. Seekins S. Yager D. Slunt H.H. Wang R. Seeger M. Levey A.I. Gandy S.E. Copeland N.G. Jenkins N.A. Price D.L. Younkin S.G. Sisodia S.S. Neuron. 1996; 17: 1005-1013Abstract Full Text Full Text PDF PubMed Scopus (1326) Google Scholar, 17Holcomb L. Gordon M.N. McGowan E. Yu X. Benkovic S. Jantzen P. Wright K. Saad I. Mueller R. Morgan D. Sanders S. Zehr C. O'Campo K. Hardy J. Prada C.M. Eckman C. Younkin S. Hsiao K. Duff K. Nat. Med. 1998; 4: 97-100Crossref PubMed Scopus (1145) Google Scholar, 18Borchelt D.R. Ratovitski T. van Lare J. Lee M.K. Gonzales V. Jenkins N.A. Copeland N.G. Price D.L. Sisodia S.S. Neuron. 1997; 19: 939-945Abstract Full Text Full Text PDF PubMed Scopus (880) Google Scholar, 19Dineley K.T. Xia X. Bui D. Sweatt J.D. Zheng H. J. Biol. Chem. 2002; 277: 22768-22780Abstract Full Text Full Text PDF PubMed Scopus (200) Google Scholar). Although such a pathogenic effect by the FAD mutations can be interpreted as “gain-of-misfunction,” the following observations do not support this simple explanation. 1) The mutations spread throughout the entire molecule. Although the majority of the mutations are missense mutations, both insertion and deletion mutations have also been identified. Thus, these mutations are indicative of a haplo-insufficiency (partial loss-of-function) or dominant-negative mechanism. Consistent with this notion, several published reports document that various PS1 FAD mutants exhibit impaired γ-secretase activities on APP, Notch, and cadherins (8Marambaud P. Wen P.H. Dutt A. Shioi J. Takashima A. Siman R. Robakis N.K. Cell. 2003; 114: 635-645Abstract Full Text Full Text PDF PubMed Scopus (420) Google Scholar, 20Song W. Nadeau P. Yuan M. Yang X. Shen J. Yankner B.A. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 6959-6963Crossref PubMed Scopus (309) Google Scholar, 21Moehlmann T. Winkler E. Xia X. Edbauer D. Murrell J. Capell A. Kaether C. Zheng H. Ghetti B. Haass C. Steiner H. Proc. Natl. Acad. Sci. U. S. A. 2002; 99: 8025-8030Crossref PubMed Scopus (237) Google Scholar, 22Wiley J.C. Hudson M. Kanning K.C. Schecterson L.C. Bothwell M. J. Neurochem. 2005; 94: 1189-1201Crossref PubMed Scopus (59) Google Scholar). 2Iwatsubo T. Curr. Opin. Neurobiol. 2004; 14: 379-383Crossref PubMed Scopus (150) Google Scholar) The most consistent effect by the PS1 FAD mutations is not a net gain of total Aβ but rather an increase in the ratio of Aβ42/Aβ40 (16Borchelt D.R. Thinakaran G. Eckman C.B. Lee M.K. Davenport F. Ratovitsky T. Prada C.M. Kim G. Seekins S. Yager D. Slunt H.H. Wang R. Seeger M. Levey A.I. Gandy S.E. Copeland N.G. Jenkins N.A. Price D.L. Younkin S.G. Sisodia S.S. Neuron. 1996; 17: 1005-1013Abstract Full Text Full Text PDF PubMed Scopus (1326) Google Scholar). This can result from elevated production of Aβ42, a reduction of Aβ40, or both combined. Indeed, several publications indicate that increase in Aβ42 is at the expense of reduced Aβ40 (23Siman R. Reaume A.G. Savage M.J. Trusko S. Lin Y.G. Scott R.W. Flood D.G. J. Neurosci. 2000; 20: 8717-8726Crossref PubMed Google Scholar, 24Steiner H. Kostka M. Romig H. Basset G. Pesold B. Hardy J. Capell A. Meyn L. Grim M.L. R. K. Haass C. Nat. Cell Biol. 2000; 2: PubMed Scopus Google Scholar), that the gain of Aβ42 be to partial of cleavage at Aβ40 or other γ-secretase the wild-type PS1 is in the in Aβ42/Aβ40 ratio are to of the mutant protein or the interactions between the type and the mutant PS1 has not been To the pathogenic of the PS1 FAD mutations, we used PS1 M146V knock-in in which the M146V FAD mutation was the mouse PS1 in an W. Sopher Miller M.W. Ware C.B. Martin G.M. Nat. Med. 1999; 5: PubMed Scopus Google Scholar) and expressed the PS1 M146V allele either with or the other allele of wild-type PS1 or As of the mutant PS1 with APP transgenic to an earlier onset of plaque pathology K. P. S. Eckman C. Harigaya Y. Younkin S. Yang F. G. 1996; PubMed Scopus Google Scholar). Surprisingly, of the allele of wild-type PS1 increased amyloid through an reduction of γ-secretase activity. and APP was against the carboxyl-terminal amino of and from and was from and peptides from PS1 M146V knock-in W. Sopher Miller M.W. Ware C.B. Martin G.M. Nat. Med. 1999; 5: PubMed Scopus Google Scholar, R. K.T. Sweatt J.D. Zheng H. 2004; PubMed Scopus Google Scholar), PS1 Zheng H. H. M.W. Price D.L. Van Sisodia S.S. Nature. 1997; PubMed Scopus Google Scholar), and Tg2576 APP transgenic K. P. S. Eckman C. Harigaya Y. Younkin S. Yang F. G. 1996; PubMed Scopus Google Scholar) have been The resulting on in with the of and and with and and on was as K.T. Xia X. Bui D. Sweatt J.D. Zheng H. J. Biol. Chem. 2002; 277: 22768-22780Abstract Full Text Full Text PDF PubMed Scopus (200) Google Scholar). The by at for and in acid for The in and with and and activity was by the in in for The with and Tris-buffered and for with in was in and at in a for in and with with a with the and the processed with the the entire The of Aβ plaques an as the total of plaques by the total for the in in for in the with for Aβ40 and Aβ42 as as the and and as which Aβ40 and Aβ42 X. Wang P. Sun X. S. H. Takashima A. E.H. Zheng H. Proc. Natl. Acad. Sci. U. S. A. 2002; 99: PubMed Scopus Google Scholar, R. M.J. H. D.B. A.G. Nature. 1999; PubMed Scopus Google Scholar). was used to which at for 1 The was in and of was with at for the for of in was to and at with the for 1 with of with of was and for at or with or and in at for in was and for 1 at the three was and for at The was by The was at by a The of Aβ40 and Aβ42 in the from the within the for in protein by and by in The with followed by and with the Aβ and on a J. M. 1996; PubMed Scopus Google Scholar). to a membrane a in phosphate-buffered for and with mouse and peptides used as for the of the Aβ in the In activity was a as Xu M. J. M.K. K.C. Proc. Natl. Acad. Sci. U. S. A. 2000; PubMed Scopus Google Scholar, Xu M. J. T. C. A. R.B. M.K. M.S. K.C. Nature. 2000; PubMed Scopus Google Scholar, L. B. Proc. Natl. Acad. Sci. U. S. A. 2004; PubMed Scopus Google Scholar). membrane proteins with and with APP The and cleavages by the and The cleavage is as in the presence of 1 γ-secretase γ-secretase activity was by from total of PS1 against possible interactions of wild-type and FAD mutant PS1 alleles on Aβ production and amyloid we crossed the PS1 M146V with Tg2576 APP transgenic to that transgenic for APP and for the PS1 M146V knock-in allele These with PS1 null to generate APP expressed on wild-type PS1 or background used in to by Aβ and and the amyloid plaque pathology in the at of As plaque deposition be in APP expressed on either or background not plaques be in the and of at this a and and a and Surprisingly, removing the wild-type PS1 allele or to a increase in the plaque and and in and a of the plaques was and plaque pathology be in mouse Introduction of the PS1 M146V FAD mutation the amyloid with to from animals, with removing the wild-type PS1 to a amyloid deposition as by both Aβ and by with and and in of Aβ40 and Aβ42 a J. M. 1996; PubMed Scopus Google Scholar) Aβ in with these that wild-type PS1 the FAD mutation-induced Aβ pathology. PS1 to Aβ and Aβ42/Aβ40 investigate the to the accelerated plaque deposition in we Aβ levels in of the by findings to of Aβ S. P. G. Yu H. Van Zheng H. Neuron. 1998; 20: Full Text Full Text PDF PubMed Scopus Google Scholar), reduction of PS1 resulted in a in both Aβ40 and Aβ42 the ratio of Aβ42/Aβ40 with consistent with the Aβ from PS1 knock-in (23Siman R. Reaume A.G. Savage M.J. Trusko S. Lin Y.G. Scott R.W. Flood D.G. J. Neurosci. 2000; 20: 8717-8726Crossref PubMed Google Scholar), of the PS1 M146V FAD mutation was by a reduction of Aβ40 and increase in Aβ42 with and of the wild-type PS1 from the to a reduction of Aβ40 Aβ42 with and and although the increase in the ratio of Aβ42/Aβ40 in was of a reduction of Aβ40 and increase in Aβ42 with of this ratio in was by an impaired Aβ40 production as Aβ42 with Therefore, exacerbated plaque pathology in 1 and is by a reduced Aβ40, the increased ratio of Aβ42/Aβ40 rather than an increased Aβ42. To support for the we the in γ-secretase activity by the membrane proteins from the wild-type PS1 or PS1 mouse with the APP and the of Aβ40 and Aβ42 production Xu M. J. M.K. K.C. Proc. Natl. Acad. Sci. U. S. A. 2000; PubMed Scopus Google Scholar, Xu M. J. T. C. A. R.B. M.K. M.S. K.C. Nature. 2000; PubMed Scopus Google Scholar, L. B. Proc. Natl. Acad. Sci. U. S. A. 2004; PubMed Scopus Google Scholar). Consistent with Aβ40 was in PS1 with wild-type of Aβ40 reduced in PS1 with both wild-type and PS1 In to the ELISA, the in γ-secretase activity not of Aβ42 in PS1 M146V with to Aβ40, levels of Aβ42 also reduced by removing the wild-type PS1 with and The in Aβ42 by the be by of the the levels of Aβ and the net effect of production and In the in γ-secretase the of Aβ the of Aβ42 to Aβ40 are in total between the with and this ratio with the of amyloid pathology. in PS1 processing of APP by β-secretases APP carboxyl-terminal which serve as substrates for γ-secretase Therefore, although Aβ40 and Aβ42 are measurements of specific γ-secretase levels of which result from insufficient processing, inversely correlate with total γ-secretase activity. Our and in γ-secretase both reduced Aβ40 as well as total Aβ in PS1 animals, the that exacerbated amyloid deposition by removing the wild-type PS1 is by an impaired γ-secretase activity. To this notion, we the activity of PS1 on PS1 substrates APP-CTF and of from wild-type PS1 and PS1 that the APP and levels the three and Although in APP or CTF levels be by wild-type and PS1 the APP and both in PS1 with and and These to the in the of APP and CTF to protein and These support that impaired γ-secretase activity in PS1 is the for the accelerated amyloid plaque pathology. of PS1 mutations in transgenic FAD mutant PS1 in the presence of mouse The resulting Aβ levels are a effect of wild-type and mutant The net effect of mutant PS1 has not been In of PS1 alter the of the γ-secretase to a In the we used the PS1 M146V knock-in in which the M146V FAD mutation was the mouse PS1 in an the of wild-type and mutant PS1 on Aβ γ-secretase processing, and amyloid plaque pathology by the PS1 M146V knock-in and PS1 alleles a Tg2576 APP transgenic Aβ and that of the PS1 M146V mutation on a Tg2576 APP transgenic background to the accelerated onset of plaque deposition from to This result is in with earlier publications and the for to investigate the interactions between the wild-type and FAD mutant PS1 L. Gordon M.N. McGowan E. Yu X. Benkovic S. Jantzen P. Wright K. Saad I. Mueller R. Morgan D. Sanders S. Zehr C. O'Campo K. Hardy J. Prada C.M. Eckman C. Younkin S. Hsiao K. Duff K. Nat. Med. 1998; 4: 97-100Crossref PubMed Scopus (1145) Google Scholar, 18Borchelt D.R. Ratovitski T. van Lare J. Lee M.K. Gonzales V. Jenkins N.A. Copeland N.G. Price D.L. Sisodia S.S. Neuron. 1997; 19: 939-945Abstract Full Text Full Text PDF PubMed Scopus (880) Google Scholar, 19Dineley K.T. Xia X. Bui D. Sweatt J.D. Zheng H. J. Biol. Chem. 2002; 277: 22768-22780Abstract Full Text Full Text PDF PubMed Scopus (200) Google Scholar). As of PS1 has been to Aβ production and amyloid pathology I. D. L. C. Van C. K. L. L. E. D. M. E. Van Leuven F. J. Neurosci. 2002; PubMed Google Scholar, C.A. G. S. Choi S.Y. D. Kirkwood A. Shen J. J. Neurosci. 2005; PubMed Scopus Google Scholar), we to plaques by PS1 Surprisingly, we that removing the wild-type PS1 allele on PS1 M146V background the amyloid pathogenesis at various including not and These a protective role of PS1 activity against FAD mutation-induced plaque to the the pathogenic effect of the PS1 M146V mutation and the protective role of wild-type ELISA, in γ-secretase activity and of of PS1 substrates APP and Although and in γ-secretase the specific γ-secretase cleavage products Aβ40 and Aβ42, the CTF levels inversely correlate with the total γ-secretase as these are the of insufficient processing by the a reduction of Aβ40 and increase of Aβ42 by the PS1 M146V mutation and an effect also in the PS1 knock-in (23Siman R. Reaume A.G. Savage M.J. Trusko S. Lin Y.G. Scott R.W. Flood D.G. J. Neurosci. 2000; 20: 8717-8726Crossref PubMed Google Scholar). Although the in γ-secretase to an increase in Aβ42 both a increase in the ratio of Aβ42/Aβ40 and consistent with the majority of published (reviewed in Ref. 2Iwatsubo T. Curr. Opin. Neurobiol. 2004; 14: 379-383Crossref PubMed Scopus (150) Google Scholar). the to the effect by the FAD mutation as increased Aβ42/Aβ40 and accelerated plaque deposition in result from production of Aβ42, a reduction of Aβ40, or both combined. the Aβ McGowan E. F. Kim J. L. J. Yu C. L. J. P. K. M. Lin G. Wang R. Eckman C.B. Hutton M. Hardy J. T. Neuron. 2005; Full Text Full Text PDF PubMed Scopus Google Scholar) that plaques can be in transgenic Aβ42 but not This a dominant effect of Aβ42 in amyloid the role of Aβ40 in this process to be of Aβ levels by that of the wild-type PS1 from to reduction of Aβ40 Aβ42 with and The in γ-secretase that both Aβ40 and Aβ42 reduced and The that reduced Aβ40 rather than increased Aβ42 is the for the Aβ42/Aβ40 ratio and and exacerbated plaque in Our are consistent with the that the ratio of Aβ42/Aβ40 is the in amyloid and we evidence that increase in this ratio can be by a reduction of Aβ40 increase in Aβ42. The for the of Aβ40 and Aβ42 in amyloid deposition to be Aβ42 is to a role in the plaque pathology T. A. H. Y. Neuron. Full Text PDF PubMed Scopus Google Scholar, Neuron. 1997; 19: Full Text Full Text PDF PubMed Scopus Google Scholar), is possible that Aβ40 with the process and the plaque In this be to Aβ40 and Aβ42 transgenic and the amyloid in these E. F. Kim J. L. J. Yu C. L. J. P. K. M. Lin G. Wang R. Eckman C.B. Hutton M. Hardy J. T. Neuron. 2005; Full Text Full Text PDF PubMed Scopus Google Scholar). of Aβ by and in γ-secretase activity resulted in and levels of Aβ42 in PS1 and the in γ-secretase activity reduction of Aβ42 of the wild-type PS1 allele from the PS1 background This be by of the the levels of Aβ, the in γ-secretase the of Aβ The Aβ is the net result of production and is to that Aβ42 have a to by from both reduction of Aβ40 but not Aβ42, and increase in the ratio of Aβ42/Aβ40 as a result of the wild-type PS1 APP and CTF as which serve as substrates for we that the PS1 are in processing APP and with wild-type or PS1 and a partial loss-of-function on total γ-secretase activity. This with the and in γ-secretase activity support for the that a reduced γ-secretase processing is the for the increased Aβ42/Aβ40 ratio and exacerbated amyloid pathology. an γ-secretase complex with an of Aβ40 and Aβ42 is a for amyloid as removing allele of PS1 not lead to in Aβ42/Aβ40 ratio with or amyloid deposition Slunt H.H. Gonzales V. Jenkins N.A. Copeland N.G. D.R. Neurobiol. 2004; PubMed Scopus Google Scholar), and of PS1 Aβ production and amyloid pathology I. D. L. C. Van C. K. L. L. E. D. M. E. Van Leuven F. J. Neurosci. 2002; PubMed Google Scholar, C.A. G. S. Choi S.Y. D. Kirkwood A. Shen J. J. Neurosci. 2005; PubMed Scopus Google Scholar). The of AD, the that the deposition of Aβ a role in pathogenesis (reviewed in Ref. J. 2002; PubMed Scopus Google Scholar). PS1 is for Aβ of presenilin and γ-secretase are as a for Our a effect of partial PS1 inhibition on amyloid pathology. findings are 1) the wild-type PS1 is protective against PS1 FAD mutation-induced amyloid and this protective effect is through a reduced γ-secretase activity and increased ratio of Our the that in the of PS1 FAD or other pathological partial of γ-secretase lead to exacerbated rather than amyloid pathology. Martin and Sopher of for the of the knock-in X. and T. for and and for with the in γ-secretase and ELISA,
Language: English
Open Access status: hybrid
Estimated APC paid: $3,430
OpenAlex ID: W2074569125
FWCI: 2.992
Cites: 42
Cited by: 78
Related to: 10